Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a clinical-stage biotechnology company focusing on mRNA cell therapies for autoimmune diseases, has announced inducement awards for five new employees. On October 1, 2024, the company granted these employees options to purchase a total of 60,961 shares of common stock at an exercise price of $17.11 per share, which was the closing price on Nasdaq on the grant date.
The options were issued under the company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and approved by the board of directors. They will vest 25% on October 1, 2025, followed by three equal annual installments, becoming fully vested on October 1, 2028. The options have a ten-year term and were granted under Nasdaq Listing Rule 5635(c)(4) as an inducement for employment.
Cartesian Therapeutics, Inc. (NASDAQ: RNAC), un'azienda biotecnologica in fase clinica che si concentra sulle terapie con mRNA per le malattie autoimmuni, ha annunciato premi di assunzione per cinque nuovi dipendenti. Il 1 ottobre 2024, l'azienda ha concesso a questi dipendenti opzioni per acquistare un totale di 60.961 azioni di azioni ordinarie a un prezzo di esercizio di 17,11 dollari per azione, che corrispondeva al prezzo di chiusura su Nasdaq nella data di concessione.
Le opzioni sono state emesse nell'ambito del Piano di Indennità per Assunzione Modificato e Ripristinato del 2018 e approvate dal consiglio di amministrazione. Esse scadono del 25% il 1 ottobre 2025, seguite da tre rate annuali uguali, diventando completamente acquisite il 1 ottobre 2028. Le opzioni hanno un termine di dieci anni e sono state concesse secondo la Regola di quotazione Nasdaq 5635(c)(4) come incentivo per l'assunzione.
Cartesian Therapeutics, Inc. (NASDAQ: RNAC), una empresa biotecnológica en etapa clínica que se enfoca en terapias celulares de ARNm para enfermedades autoinmunes, ha anunciado recompensas de inducido para cinco nuevos empleados. El 1 de octubre de 2024, la compañía otorgó a estos empleados opciones para comprar un total de 60,961 acciones de acciones comunes a un precio de ejercicio de 17.11 dólares por acción, que fue el precio de cierre en Nasdaq en la fecha de concesión.
Las opciones fueron emitidas bajo el Plan de Incentivos de Inducción Modificado y Restablecido de 2018 y aprobadas por la junta directiva. Se consolidarán en un 25% el 1 de octubre de 2025, seguidas de tres igualdades anuales, convirtiéndose completamente consolidadas el 1 de octubre de 2028. Las opciones tienen un plazo de diez años y fueron otorgadas bajo la Regla de Cotización de Nasdaq 5635(c)(4) como incentivo para el empleo.
Cartesian Therapeutics, Inc. (NASDAQ: RNAC)은 자가면역 질환을 위한 mRNA 세포 치료제에 초점을 맞춘 임상 단계의 생명공학 회사로, 새로운 직원 다섯 명을 위한 유인賞을 발표했습니다. 2024년 10월 1일, 회사는 이 직원들에게 60,961주의 보통주를 주당 17.11달러의 가격으로 구매할 수 있는 선택권을 부여했습니다. 이 가격은 부여 날짜의 나스닥 종가에 해당합니다.
이 선택권은 회사의 수정된 2018년 고용 유인 인센티브 상여 계획에 따라 발행되었으며 이사회에서 승인되었습니다. 이들은 2025년 10월 1일에 25%가 보장되며, 후속으로 세 해마다 동일한 할부로 지급되며 2028년 10월 1일에 전액 보장됩니다. 이 선택권은 10년의 유효기간을 가지며, 고용 유인을 위한 나스닥 상장 규칙 5635(c)(4)에 따라 부여되었습니다.
Cartesian Therapeutics, Inc. (NASDAQ: RNAC), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapies cellulaires à ARNm pour les maladies auto-immunes, a annoncé des primes d'incitation pour cinq nouveaux employés. Le 1er octobre 2024, l'entreprise a accordé à ces employés des options d'achat d'un total de 60 961 actions ordinaires au prix d'exercice de 17,11 $ par action, qui correspondait au prix de clôture de Nasdaq à la date d'octroi.
Les options ont été émises dans le cadre du Plan de primes d'incitation à l'emploi amendé et rétabli de 2018 et ont été approuvées par le conseil d'administration. Elles deviennent acquises à 25 % le 1er octobre 2025, suivies de trois versements annuels égaux, devenant totalement acquises le 1er octobre 2028. Les options ont une durée de dix ans et ont été accordées en vertu de la règle d'inscription Nasdaq 5635(c)(4) comme incitation à l'emploi.
Cartesian Therapeutics, Inc. (NASDAQ: RNAC), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf mRNA-Zelltherapien für Autoimmunerkrankungen spezialisiert hat, hat Induktionsprämien für fünf neue Mitarbeiter angekündigt. Am 1. Oktober 2024 gewährte das Unternehmen diesen Mitarbeitern Optionen zum Kauf von insgesamt 60.961 Aktien zu einem Ausübungspreis von 17,11 USD pro Aktie, was dem Schlusskurs an der Nasdaq am Tag der Gewährung entspricht.
Die Optionen wurden im Rahmen des geänderten und erneuerten 2018 Beschäftigungs-Induktions-Incentive-Programms ausgegeben und vom Vorstand genehmigt. Sie werden am 1. Oktober 2025 zu 25% fällig, gefolgt von drei gleichmäßigen jährlichen Raten, und werden am 1. Oktober 2028 vollständig fällig. Die Optionen haben eine Laufzeit von zehn Jahren und wurden gemäß der Nasdaq-Listungsregel 5635(c)(4) als Anreiz für die Beschäftigung gewährt.
- Cartesian Therapeutics is attracting new talent with stock options as incentives
- The company is expanding its workforce, potentially indicating growth or new projects
- Granting of stock options may lead to potential dilution for existing shareholders
GAITHERSBURG, Md., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to five new employees. On October 1, 2024, the Company issued to these employees options to purchase an aggregate of 60,961 shares of the Company’s common stock with an exercise price of
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is an mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.
Contact Information:
Investor Contact:
Melissa Forst
Argot Partners
cartesian@argotpartners.com
Media Contact:
David Rosen
Argot Partners
david.rosen@argotpartners.com
FAQ
How many new employees received stock options from Cartesian Therapeutics (RNAC) on October 1, 2024?
What is the exercise price of the stock options granted by Cartesian Therapeutics (RNAC) on October 1, 2024?
When will the stock options granted by Cartesian Therapeutics (RNAC) on October 1, 2024, be fully vested?
How many shares of common stock are covered by the options granted by Cartesian Therapeutics (RNAC) on October 1, 2024?
